Indivior is a global pharmaceutical company singularly focused on delivering evidence-based treatment for opioid use disorder (OUD). For more than 25 years, Indivior has been dedicated to advancing evidence-based treatment for people living with OUD, working to transform OUD from a global human crisis to a recognized and treated chronic disease. Headquartered in Richmond, Virginia, with operations spanning the United States and United Kingdom, Indivior employs over 700 individuals worldwide who are driven by a shared mission to help patients reclaim their lives.
The company's specialized focus has resulted in a portfolio of innovative treatments and a robust pipeline of product candidates designed to expand on their heritage in addiction medicine. Indivior's products include SUBLOCADE, a monthly injectable buprenorphine, demonstrating measurable clinical and economic benefits through real-world evidence. The company culture emphasizes developing and delivering long-acting, evidence-based treatments that build solutions to restore hope - one life, one family, and one community at a time.
